Randomized trial of statin administration for myocardial injury - Is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention?

Circulation Journal

Volumn 71, Issue 8, 2007, Pages 1225-1228

  Kinoshita, Masayoshi ^a,b   Matsumura, Shin Ichirou ^a,b   Sueyoshi, Kouichirou ^a,b   Ogawa, Satoshi ^a   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Shizuoka Municipal Shimizu Hospital   (Japan)

Author keywords

Angioplasty; Cholesterol; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CREATINE KINASE MB; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RAPAMYCIN; TICLOPIDINE; TROPONIN T;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DRUG ELUTING STENT; FEMALE; HEART MUSCLE INJURY; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVASCULAR ULTRASOUND; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; HEART INJURIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; STENTS; TROPONIN T;

EID: 34547596559     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1225     Document Type: Article

References (29)

1. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991; 17: 621-626.
2. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-251.
3. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528-1536.
4. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002; 23: 869-876.
5. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003; 42: 1406-1411.
6. Saucedo JF, Mehran R, Dangas G, Hong MK, Lansky A, Kent KM, et al. Long-term clinical events following creatine kinase - myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000; 35: 1134-1141.
7. Herrmann J, Von Birgelen C, Haude M, Volbracht L, Malyar N, Eggebrecht H, et al. Prognostic implication of cardiac troponin T increase following stent implantation. Heart 2002; 87: 549-553.
8. Kurz DJ, Naegeli B, Bertel O. A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting. Am Heart J 2000; 139: 35-43.
9. Wang FW, Osman A, Otero J, Stouffer GA, Waxman S, Afzal A, et al. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 2003; 107: 2914-2919.
10. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators: Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998; 352: 87-92.
11. Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: Benefit is extended to improvement in intermediate-term survival. Circulation 2000; 102: 166-172.
12. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106: 2180-2183.
13. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-696.
14. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-678.
15. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, et al. Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Eur Heart J 2004; 25: 1822-1828.
16. Mulukutla SR, Marroquin OC, Smith C, Varghese R, Anderson WD, Lee JS, et al. Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. Am J Cardiol 2004; 94: 1363-1366.
17. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: Identification of an early risk period: Importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002; 106: 1205-1210.
18. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001; 286: 64-70.
19. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107: 1750-1756.
20. Correia LC, Sposito AC, Lima JC, Magalhaes LP, Passos LC, Rocha MS, et al. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 2003; 92: 298-301.
21. Jones SP, Lefer DJ. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand 2001; 173: 139-143.
22. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 247-251.
23. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001; 38: 2006-2012.
24. Wassmann S, Ribaudo N, Faul A, Laufs U, Bohm M, Nickenig G. Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl. Am J Cardiol 2004; 93: 84-88.
25. Katsumoto M, Shingu T, Kawashima R, Nakata A, Nomura S, Chayama K. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 2005; 69: 1547-1555.
26. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534.
27. 2+ and membrane dynamics in patients with primary hypercholesterolemia: Effects of pravastatin. Arterioscler Thromb Vasc Biol 1995; 15: 759-764.
28. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 247-251.
29. Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, et al. Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 2000; 83: 688-692.